Cysteine-rich Region of Raf-1 Interacts with Activator Domain of Post-translationally Modified Ha-Ras (*)

The interaction between “switch I/effector domain” of Ha-Ras and the Ras-binding domain (RBD, amino acid 51-131) of Raf-1 is essential for signal transduction. However, the importance of the “activator domain” (approximately corresponding to amino acids 26-28 and 40-49) of Ha-Ras and of the “cysteine-rich region” (CRR, amino acids 152-184) of Raf-1 have also been proposed. Here, we found that Raf-1 CRR interacts directly with Ha-Ras independently of RBD and that participation of CRR is necessary for efficient Ras-Raf binding. Furthermore, Ha-Ras carrying mutations (N26G and V45E) in the activator domain failed to bind CRR, whereas they bound RBD normally. On the contrary, Ha-Ras carrying mutations in the switch I/effector domain exhibited severely reduced ability to bind RBD, whereas their ability to bind CRR was unaffected. Mutants that bound to either RBD or CRR alone failed to activate Raf-1. Ha-Ras without post-translational modifications, which lacks the ability to activate Raf-1, selectively lost the ability to bind CRR. These results suggest that the activator domain of Ha-Ras participates in activation of Raf-1 through interaction with CRR and that post-translational modifications of Ha-Ras are required for this interaction.

[1]  C. Der,et al.  Two Distinct Raf Domains Mediate Interaction with Ras (*) , 1995, The Journal of Biological Chemistry.

[2]  X. F. Zhang,et al.  Identification of the sites of interaction between c-Raf-1 and Ras-GTP. , 1995, Oncogene.

[3]  S. Yokoyama,et al.  A Constitutive Effector Region on the C-terminal Side of Switch I of the Ras Protein (*) , 1995, The Journal of Biological Chemistry.

[4]  R. Jove,et al.  Raf-1 N-terminal sequences necessary for Ras-Raf interaction and signal transduction , 1995, Molecular and cellular biology.

[5]  J. Troppmair,et al.  The ins and outs of Raf kinases. , 1994, Trends in biochemical sciences.

[6]  T. Kataoka,et al.  Quantitative analysis of mutually competitive binding of human Raf-1 and yeast adenylyl cyclase to Ras proteins. , 1994, The Journal of biological chemistry.

[7]  L. Williams,et al.  The post-translational modification of ras p21 is important for Raf-1 activation. , 1994, The Journal of biological chemistry.

[8]  M. Shirouzu,et al.  Mutations that abolish the ability of Ha-Ras to associate with Raf-1. , 1994, Oncogene.

[9]  X. F. Zhang,et al.  Critical binding and regulatory interactions between Ras and Raf occur through a small, stable N-terminal domain of Raf and specific Ras effector residues , 1994, Molecular and cellular biology.

[10]  Jonathan A. Cooper,et al.  A single amino acid change in Raf-1 inhibits Ras binding and alters Raf-1 function. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Hancock,et al.  Activation of Raf as a result of recruitment to the plasma membrane. , 1994, Science.

[12]  Sally J. Leevers,et al.  Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane , 1994, Nature.

[13]  S. Elledge,et al.  Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1 , 1993, Nature.

[14]  Jonathan A. Cooper,et al.  Mammalian Ras interacts directly with the serine/threonine kinase raf , 1993, Cell.

[15]  M. Marshall,et al.  The effector interactions of p21ras. , 1993, Trends in biochemical sciences.

[16]  C J Marshall,et al.  Protein prenylation: a mediator of protein-protein interactions. , 1993, Science.

[17]  T. Kataoka,et al.  The effect of posttranslational modifications on the interaction of Ras2 with adenylyl cyclase , 1993, Science.

[18]  M. Nakafuku,et al.  Function of Ras as a molecular switch in signal transduction. , 1992, The Journal of biological chemistry.

[19]  T. Kataoka,et al.  The posttranslational processing of ras p21 is critical for its stimulation of yeast adenylate cyclase , 1992, Molecular and cellular biology.

[20]  U. Rapp,et al.  Serum-, TPA-, and Ras-induced expression from Ap-1/Ets-driven promoters requires Raf-1 kinase. , 1992, Genes & development.

[21]  A. Sizeland,et al.  Asparagine 26, glutamic acid 31, valine 45, and tyrosine 64 of Ras proteins are required for their oncogenicity. , 1992, The Journal of biological chemistry.

[22]  S. Yokoyama,et al.  Identification of amino acid residues of Ras protein that are essential for signal‐transducing activity but not for enhancement of GTPase activity by GAP , 1991, FEBS letters.

[23]  E. Scolnick,et al.  Identification of amino acid residues required for Ras p21 target activation , 1991, Molecular and cellular biology.

[24]  K. Kaibuchi,et al.  A stimulatory GDP/GTP exchange protein for smg p21 is active on the post-translationally processed form of c-Ki-ras p21 and rhoA p21. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[25]  S H Kim,et al.  Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins. , 1992, Science.

[26]  W. Kabsch,et al.  Refined crystal structure of the triphosphate conformation of H‐ras p21 at 1.35 A resolution: implications for the mechanism of GTP hydrolysis. , 1990, The EMBO journal.

[27]  V. Stanton,et al.  Definition of the human raf amino-terminal regulatory region by deletion mutagenesis , 1989, Molecular and cellular biology.

[28]  D. Lowy,et al.  p21-ras effector domain mutants constructed by "cassette" mutagenesis , 1988, Molecular and cellular biology.

[29]  H. Fritz,et al.  Oligonucleotide-directed construction of mutations via gapped duplex DNA. , 1987, Methods in enzymology.

[30]  E. Scolnick,et al.  Identification of effector residues and a neutralizing epitope of Ha-ras-encoded p21. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[31]  K. Mullis,et al.  Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. , 1985, Science.

[32]  T. Bonner,et al.  Structure and biological activity of human homologs of the raf/mil oncogene , 1985, Molecular and cellular biology.